Adjuvant Molecular Hydrogen Therapy in SLE-associated Pulmonary Arterial Hypertension: A Case Report on Immunomodulatory Effects on Regulatory and Effector Lymphocytes.
Chin Liu, Jeng-Wei Lu, Chun-Hsien Wu, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Kuang-Yih Wang, Feng-Cheng Liu · In vivo (Athens, Greece) · 2026
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In participants with systemic lupus erythematosus (SLE), this case study suggests that molecular hydrogen therapy may be a promising treatment for patients with SLE-PAH, particularly due to its immunomodulatory effects. These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence blood-pressure regulation.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in participants with systemic lupus erythematosus (SLE). This case study suggests that molecular hydrogen therapy may be a promising treatment for patients with SLE-PAH, particularly due to its immunomodulatory effects.
What the Researchers Studied
The researchers studied participants with systemic lupus erythematosus (SLE).
What Effects Did Molecular Hydrogen Have?
This case study suggests that molecular hydrogen therapy may be a promising treatment for patients with SLE-PAH, particularly due to its immunomodulatory effects. Molecular hydrogen therapy, a selective antioxidant and anti-inflammatory agent, may modulate the immune responses seen in autoimmune diseases. CASE REPORT: A 42-year-old Taiwanese woman with SLE-PAH received hydrogen capsule therapy, during which serial immunophenotyping revealed dynamic changes in suppressive markers including programmed cell death protein 1 (PD1) and Fas cell surface death receptor (FAS), as well as regulatory T- and B-cell subsets.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence blood-pressure regulation and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a case report. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as case report with human clinical evidence. The research population or model was participants with systemic lupus erythematosus (SLE).
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.